Gabriella Liszkay

Gabriella Liszkay

Ráth György Str. 7-9
Budapest, BU 1122, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Journal: ESMO open

Published: January 03, 2026

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 23, 2025

Characterization of Melanoma in Hungary Based on a Retrospective Single-Center Study Between 2001 and 2018.

Characterization of Melanoma in Hungary Based on a Retrospective Single-Center Study Between 2001 and 2018.

Journal: Cancers

Published: May 19, 2025

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.

Journal: ESMO open

Published: October 22, 2024

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 03, 2024

Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma.

Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma.

Journal: Cell metabolism

Published: August 26, 2023

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 28, 2023

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: July 17, 2023

Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients.

Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients.

Journal: Cancers

Published: June 30, 2023

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.

Journal: Future oncology (London, England)

Published: June 13, 2023

Electrochemotherapy in metastatic melanoma

Electrochemotherapy in metastatic melanoma

Journal: Orvosi hetilap

Published: May 08, 2023

Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019.

Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 18, 2022

Showing 1-12 of 68

Last Updated: 09/26/2026